Reimbursement Is Neurotech's Biggest Risk with Juan-Pablo Mas
In this episode, your host, Liz Moyles, is joined by Juan-Pablo Mas, Managing Director at Action Potential VC to talk about investing at the frontier of neurotech and bioelectronic medicine, and why reimbursement, not technology, is so often the make-or-break risk.
Juan-Pablo traces his path from electrical engineering and a formative stint in Medtronic's cardiovascular division, through Stanford Biodesign and his first venture roles at Morgenthaler and Lightstone, to a decade investing in the brain and nervous system at Action Potential and now the Synapse Fund.
He explains what he looks for…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.